Blackberry-induced hand-foot skin reaction to sunitinib
- 8 November 2008
- journal article
- case report
- Published by Springer Nature in Investigational New Drugs
- Vol. 27 (4) , 389-390
Abstract
Sunitinib is an orally administered small molecule that was approved by the US Food and Drug Administration in January 2006 as monotherapy for the treatment of patients with advanced renal cell carcinoma (RCC) and patients with gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. Data pooled from multiple sunitinib dose-escalation trials showed that sunitinib is associated with various adverse events, with HFSR occurring in up to 20% of patients. We describe a 48-year-old woman with a history of metastatic colorectal cancer treated with single-agent sunitinib who developed pain and tenderness in areas of friction secondary to Blackberry use, and was diagnosed with trauma-induced hand-foot skin reaction (HFSR) secondary to sunitinib therapy.Keywords
This publication has 6 references indexed in Scilit:
- Food and Drug Administration Drug Approval Summary: Sunitinib Malate for the Treatment of Gastrointestinal Stromal Tumor and Advanced Renal Cell CarcinomaThe Oncologist, 2007
- Hand-Foot Syndrome and Seborrheic Dermatitis-Like Rash Induced by Sunitinib in a Patient With Advanced Renal Cell CarcinomaJournal of Clinical Oncology, 2006
- Molecular Mechanisms of VEGF-A Action during Tissue RepairJournal of Investigative Dermatology Symposium Proceedings, 2006
- Subungual Splinter Hemorrhages: A Clinical Window to Inhibition of Vascular Endothelial Growth Factor Receptors?Annals of Internal Medicine, 2005
- Therapeutic Options in the Management of Colon Cancer: 2005 UpdateClinical Journal of Oncology Nursing, 2005
- Palmar-Plantar ErythrodysesthesiaClinical Journal of Oncology Nursing, 2005